fbpx

Brief

AMR Policy Dialogue: Driving Innovative Solutions for Antimicrobial Discovery

Published on 1 June 2022

Antimicrobial resistance (AMR) is a global strategic priority and sits within the UK Government’s National Risk Register. By 2050, AMR is predicted to cause 10 million deaths, more than cancer. In 2019 alone, there were an estimated 4.95 million deaths associated with bacterial AMR.

Although global pharmaceutical research and development (R&D) spend continues to increase year on year, research into antimicrobial drug discovery is not currently an attractive commercial investment. This has had two major consequences: an ongoing decline of human capital for R&D in this field, and a decline over the longer term in availability of therapeutically effective antibiotics and other antimicrobial agents.

Concerted and coordinated efforts are needed to translate high-level policy commitments into strategic actions for long-term funding and support for the R&D of new antimicrobials.

Cite this publication

Ghionis, A.; Barker, T. and Dowson, C. (2022) AMR Policy Dialogue: Driving Innovative Solutions for Antimicrobial Discovery

Citation copied

Authors

Image of Tom Barker

Tom Barker

Senior Health & Nutrition Convenor

Alexander Ghionis

Christopher Dowson

Publication details

published by
University of Warwick
language
English

Share

About this publication

Related content